Roche Tries Genentech Formula In Japan: Chugai Deal Follows 1990 Model
Executive Summary
Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms
You may also be interested in...
Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said
Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said
Roche Pipeline Potency Validates No-Merger Stance, Company Says
Roche has the third largest pipeline of new molecular entities in development in the drug industry, the company maintained during an R&D day in New York City May 6